$ACAD ACADIA Pharmaceuticals Inc- Base- Base resolution imminent. - $19.13 / $19.44 / $19.77 / $20.00 / $20.31Longby xclusivetradingeurope0
ACAD Stock Soared to a Four-Month High. Acadia Pharmaceuticals shares are trading higher Wednesday after the company won summary judgement in a patent suit. Just then Acadia Surged upto 33% in regards to the news. Acadia Pharmaceuticals (ACAD) notched a win in a patent battle Wednesday pertaining to its Parkinson's drug, Nuplazid. ACAD stock soared to a four-month high. ACAD Stock: Cashing In On Nuplazid Nuplazid is an important drug for Acadia. It's currently approved to treat patients with psychosis due to Parkinson's disease. In the September quarter, Nuplazid brought in $144.8 million in sales, accounting for more than 68% of total sales. NASDAQ:ACAD is trading above the 50, 100, & 200-day moving average indicating a Bullish Bias. Longby DEXWireNews2
$ACAD will need to finish correction before starting a long NASDAQ:ACAD - expecting a turn 180 degree and beginning of the moddle-term long position. NASDAQ:ACAD :: HKEX:18 -> HKEX:30 ::67%::Oct 2023 Does not constitute a recommendation. #investing #stocks #idea #forecast #furoreggs Please, subscribe and challenge my point of view )Longby furoreggsUpdated 111
ACAD - Breakout IdeaA small channel up within a larger channel down I expect a breakout up to the top of the larger down channel This works well with a curved bowl recovery structure by Bixley0
ACADIA Pharmaceuticals Inc - Biotech Run Up: Catalyst 3/12/23ACADIA Pharmaceuticals Inc. has a significant catalyst event scheduled for March 12th, 2023. After a prolonged decline, the stock has rebounded and broken out of a downward trend, indicating potential for upward movement. Investors should keep an eye on this biotech company as it approaches the catalyst date. Additional information on biotech catalysts can be found at biopharmcatalyst.comLongby BioPharmCatalyst225
Acadia Beautiful tap of long term support could signal a large double bottom. If we can pop and close above 20$ could bring us to retest upper resiatnce of 25 or 27$. If we fail 20$ I would look for a retest or 16$ range huge buy volume came in at 16$ I wouldn’t chase this but keep on radar for a pull backLongby Erictaylor0
ACADIABREAKING OUT OF ANOTHER bullflag or bull poennat break 24$ and we are looking foir a nice push!! target 27.55Longby Erictaylor1
Acadia I had this mapped out but I misse the trade! Damn! What do I do!? We’ll I’ll tell you, I don’t come in here now and FOMO. I draw some fibs and look for previous resiatnce. I see a lot o wicks and no candles closing above .382 from recent high to low of 21.07 This price is 22.48 I have some bids there. I see .618 at 22.14. This is also the low supprt of recent bull flag breakout. These are my levels I’m putting some buy orders out here. If we lost these support there is a big buyer at 21.08 if price does come all the way back down for another gift. This should reach 27.48 AT LEAst c I’ll be swinging this to that price target. Good luck!! Longby Erictaylor0
Big move coming, which way is the question..NASDAQ:ACAD .. I have been along with this one for a few months now. Around this price range is where we see big-time moves. This $21.88 level is a key level for this stock. It has been in a downtrend since it hit its 3 month high at the end of December. With how the market has been to begin this year, the downtrend seems more likely to continue. There is a good chance we see a bounce at this level considering there is not much volume until that $21.88 level, but only to again try to break out of this downtrend. I bet we see this big level tested in the next couple of days to see if it breaks down. by keekthedeek1
ACAD, correcite move formingACAD seems to me it finished the first wave of an A-B-C zig-zag pattern, we should expect now a 3 waves move to the upside with price not retracing more than 61,8% Fib . Correction might take us to 6,13$-3,53 $ range.Shortby Flpati0
ACAD. HTF support, lovely range. Good afternoon, Acadia Pharmaceuticals has been trading rangebound since 2013. There is RSI bullish divergence on the weekly timeframe and bull fisher divergence, powerful signals placed in the demand zone. Big swings on this a financial asset. NFA and always DYOR. Longby Chopstick_Charlie0
ACAD back in the gamePossible Reversal trade: After a huge gap (-40%) price approaching support level ($14.4) Volume spikes during the last 6 months. RSI growing (but still under 50) Earning call 11/9 Longby Vladimir_Ch3
ACAD bullish butterflyACAD bullish butterfly ACAD bullish butterfly ACAD bullish butterfly ACAD bullish butterfly ACAD bullish butterflyLongby nicugosa0
ACADIA Pharmaceuticals Inc 🧙Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!Longby yura_trades221
Acadia pharmOn March 9, the FDA identified flaws in ACADIA's application for a new drug for Pimavanserin to treat hallucinations and delusions associated with psychosis and dementia. By April 3, Acadia is likely to receive a full response letter from the FDA. DRP approval of Pimavanserin is unlikely, but possible. The stock bounced off 24.00, then 26.00 and 27.00. The figure W is formed Accumulation for a jump takes 4 days, then a shot. Risk 1: 5Longby monsRUS0
Pull Back FishingLong fall after a disappointing study result, I think? Earnings May 26th. Triple top noted but has fallen more than this structure would measure. No recommendation Sometimes when stocks gap down, price goes up only to fall again (dead cat bounce) so always good to be sure the bottom is the bottom. Gaps down are bearish and even though this gap will most likely fill one day, it is still good to get a healthy long entry level. The market can gravitate toward uncertainty.by lauralea1
ACAD (ACADIA PHARMACEUTICALS INC) BUY ACAD LONG SET UP, ACAD Gapped down over 25% to a New 52 week low. Price should bounce and fill in the Gap in the market ACAD also filled its previous Buy gap from Sep 4th 2019 Title: Buy ACAD (ACADIA Pharmaceuticals) Asset: Stock Platform: Robinhood/WeBull/Etrade/ 401k account Symbol: ACAD Type: Buy Market Execution / Buy Limit Time Frame: 1D Entry Price 1: $26.50 ACTIVE Entry Price 2: $22.50(PENDING) Stop Loss: $19.50 (70 Pips) Take Profit 1: $33.00 (70 pips) Take Profit 2: $38.00 (140 pips) Take Profit 3: $44.00 (200 pips) Take Profit 4: $54.00 (300pips) Status: 🏃🏽♂️Active🏃🏽♂️ Sector: Health Technology Industry: Biotechnology ACADIA Pharmaceuticals operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R Brann on July 16, 1993 and is headquartered in San Diego CALongby MavRich_Trading333
ACAD: Chance for a big pullbackSo what has caused such plummet? I've carried out a research and found out. 😀 Stock has declined due to the simple fact that FDA has requested the specific requirements for the drug labeling. By the way, The drug (Pimavanserin) has already been approved by FDA for quite long time. So in general, regulatory setback was in post-marketing requirements. The situation wasn't as tragic as market has reacted to. The problem has a simple solution. In other words, the company should just mobilize their effort to change the label to the one asked by FDA. Moreover, If you check the production pipeline, you'll see that it's not the only drug the company is making. Definitely waiting for a pullback, or I even dare to call it a recovery. I mean look at the weekly chart on the right. It literally screams for bulls. Left chart shows significant levels for each stop of supposed bullish wave based on fib sequence of initial green candle on the bottom. Fib channel is mounted to the parallel angle of decline on top and bottom patterns. Combo of these two tools will allow to trace the level at which the pullback will be on its reversal stage. Longby fractUpdated 4416
Possible C&H forming?She also has a catalyst event coming on April 3rd. Input and thoughts appreciated.by Danzalew990
ADD on 41 USD for strong buyRSI is then 30 on the 2 day chart (strong buy signal)--- STOCK bottomed out Trendline from 2019 will hold there FIB 0.61 (golden fib zone) will hold there by legendtrader6661
$ACADCup & Handle pattern Daily hidden bullish divergence on the MACD and RSI The 'Handle' respected the 0.618 fib. retracement well Stop = Under 0.618 fib. retracement Target = 1.618 fib extensionby Joshh_TradessUpdated 0